Refine by
Health Threat Equipment & Supplies
6 equipment items found
Manufactured by:VBI Vaccines Inc. based inCambridge, MASSACHUSETTS (USA)
VLPs can be customized to present any protein antigen, including multiple antibody and T cell targets, making them ideal technologies for the development of both prophylactic and therapeutic vaccines. Moreover, most of the emerging and re-emerging viruses that pose significant health threats are enveloped viruses, making them prime targets for VBI’s ...
by:T2 Biosystems, Inc. based inLexington, MASSACHUSETTS (USA)
The T2Cauris™ Panel RUO provides direct detection of the emerging superbug Candida auris in patient skin and patient blood and is now available for research use. The Centers for Disease Control and Prevention (CDC) validated the T2Cauris™ Panel RUO swab test on patient skin samples and published their findings in Mycoses.1 ...
by:National Resilience, Inc. based inSan Diego, CALIFORNIA (USA)
Now more than ever, global vaccine innovators need a biomanufacturing partner with the ability to adapt skillfully and the capacity to scale rapidly. Enter ...
Manufactured by:Amivas (US), LLC based inFrederick, MARYLAND (USA)
A Severe Malaria Treatment, Vital for the US Healthcare Community. No FDA-approved injectable malaria medication has been available in the US since IV quinidine was discontinued in early 2019. Artesunate for Injection fills this ...
by:Kephera Diagnostics, LLC based inFramingham, MASSACHUSETTS (USA)
Kephera is developing a test for Zika virus infection with support from a grant from the National Institutes of Health. Kephera’s Zika project is based on the identification of Zika-specific and Dengue-specific epitopes within the viral genome, from which an immunoassay will be developed in convenient and cost-effective ELISA format, and ultimately translated to point-of-care format. To ...
by:Glycotest, Inc based inMerion, PENNSYLVANIA (USA)
Glycotest blood tests are being developed to provide information on the likelihood of serious liver disease like cancer or fibrosis-cirrhosis by employing technology designed to measure two kinds of disease signals: The amount of the monosaccharide fucose that appears abnormally on certain serum glycoproteins—to indicate likelihood of disease. The pattern of glycoproteins that is abnormally ...